Pancreatic cancer, one of the deadliest human malignancies, has a dismal 5-year survival rate of 9%. The 20 high mortality rate can be attributed to multiple factors, including late diagnosis and lack of effective 21 therapies. KRAS is the most commonly mutated gene in pancreatic cancer, but clinical agents that 22 directly target mutant KRAS are not available. Several effector pathways are activated downstream of 23 oncogenic Kras, including MAPK signaling. MAPK signaling can be inhibited by targeting MEK1/2; 24 unfortunately, this approach has been largely ineffective in pancreatic cancer. Here, we set out to 25 identify mechanisms of MEK inhibitor resistance in pancreatic cancer using primary mouse and human 26 3D organoid cultures. We optimized the culture of pancreatic tumor organoids that utilized Matrigel as a 27 basement membrane mimetic, facilitating polarized growth. Pancreatic tumor organoids recapitulated 28 mutant KRAS dependency and recalcitrance to MEK inhibition. Treatment of the organoids with 29 trametinib, a MEK inhibitor, had only a modest effect on these cultures. We observed that cells adjacent 30 to the basement membrane mimetic Matrigel survived MEK inhibition, while the cells in the interior 31 layers underwent apoptosis. Our findings suggested that basement membrane attachment provided 32 survival signals. We thus targeted integrin β1, a mediator of extracellular matrix contact, and found that 33 combined MEK and integrin β1 inhibition bypassed trametinib resistance. Our data support exploring 34 integrin signaling inhibition as a component of combination therapy in pancreatic cancer. 35 36 basement membrane mimetic have a survival advantage. In this 3D system, Matrigel coats the entire 131 outside of the cluster in vitro, so following fixation and sectioning, the outermost layer of cells in cluster 132 cross-sections are considered adjacent to the Matrigel ( Supplementary Fig. 1 ). This can be visualized by 133
Introduction 37
Pancreatic Ductal Adenocarcinoma (PDAC), accounting for 90% of pancreatic neoplasms, is projected to 38 become the 2nd leading cause of cancer death in the US by 2030 [1, 2] . Almost 95% of PDAC cases 39 express a mutated form of the GTPase KRAS [3] . Activating mutations in KRAS (the most prevalent being 40 KRAS G12D ), lead to constitutive, aberrant activation of KRAS and subsequent neoplasia [4] . The Mitogen-41 3 activated protein kinase (MAPK) pathway is a downstream effector of oncogenic KRAS and its activation 42 promotes cell growth, survival, and proliferation [5] . While KRAS inhibitors are currently not available, 43 the MAPK signaling pathway can be targeted by multiple FDA-approved agents, many of which target 44 the key kinases MEK1/2 [6, 7] . Inhibition of MAPK signaling blocks the onset of carcinogenesis [8] , 45 possibly by interfering with the dedifferentiation of acinar cells to duct-like cells that are susceptible to 46 transformation, a process known as acinar-ductal metaplasia (ADM) . MEK inhibition has been tested in 47 pancreatic cancer as a single-agent therapy, as well as in combination with Phosphoinositide Kinase-3 48 (PI3K) pathway inhibition (targeting another downstream effector of KRAS [9, 10]). Unfortunately, these 49 efforts have failed to demonstrate clinical benefit [11] . 50 51 MEK inhibition using trametinib is tolerated in the PDAC patient population [10] . We set out to 52 understand mechanisms of resistance to trametinib with the goal to identify potential new combination 53 approaches for pancreatic cancer therapy. Since the resistance to trametinib is observed in tumor cells 54 in isolation, we focused here on the cell-autonomous mechanisms of resistance, using a three 55 dimensional (3D) in vitro model of PDAC. In this study, we found that cells adjacent to the basement 56 membrane exhibit a survival advantage over cells lacking ECM signaling when administered a MEK 57 inhibitor. Furthermore, KRAS effector signaling is reduced to only ECM-adjacent cells when given an β1 58 integrin neutralizing antibody. Lastly, dual blockade of both MEK and β1 integrin significantly increased 59 PDAC cell apoptosis compared to singular inhibition of MEK or β1 integrin. These results indicate that β1 60 integrin plays an important role in mediating PDAC resistance to MEK inhibition. 61 62
Results 63
Establishing a 3D culture model of pancreatic cancer. 64 4 The iKras*;p53* mouse model of pancreatic cancer mimics the progression of the human disease [12] . In 65 this model, oncogenic Kras G12D (Kras*) expression is regulated by a tet-response element, while mutant 66 p53 R172H is constitutively expressed in the pancreas, allowing for inducible and reversible expression of 67 Kras* upon administration or removal of doxycycline (DOX), respectively (Fig. 1a) . The generation of cell 68 lines from primary tumors formed in iKras*;p53* pancreata was previously described [13] . 69 Subsequently, iKras*;p53* PDAC cells were passaged and maintained in two-dimensional culture in 70 presence of DOX to maintain expression of oncogenic Kras (Fig. 1b ). 71 72 Growth in 3D was achieved by trypsinizing and resuspending PDAC cells in single-cell-suspension with 73 cell culture medium that contained DOX and solubilized Growth Factor Reduced (GFR) Matrigel, a 74 basement membrane mimetic comprised of extracellular matrix (ECM) proteins: laminins, Type IV 75 collagen (Col4), and entactin. Matrigel facilitates 3D proliferation and adhesion of cells, interactions that 76 may regulate crucial aspects of cancer molecular pathogenesis in vivo [14] . Subsequently, PDAC cells in 77 suspension were plated atop a layer of solidified GFR Matrigel. Approximately 6 days following plating, 78 PDAC cells organized into 3D, discrete clusters that were fixed for histochemical analysis ( Fig. 1c-e ). To 79 determine whether cells in this 3D assay recapitulated oncogenic Kras* dependency observed in vivo, 80 cells were randomized into two experimental groups: DOX was either withheld or administered to the 81 media at the time of plating to inactivate or activate oncogenic Kras* expression, respectively. 82
Brightfield microscopy was used to monitor cell growth and ImageJ was used to measure PDAC cluster 83 area ( Supplementary Fig. 1 ). DOX administration induced an approximate 4-fold increase in average 84 cluster area ( Fig. 1f , g, Supplementary Fig. 2 ), indicating that oncogenic Kras* expression was sufficient 85 to facilitate tumor cell growth and proliferation in this model. These results are consistent with previous 86 in vivo and in vitro findings [13] . 87 5 88 In 2D, oncogenic Kras had a limited effect on cell viability ( Supplementary Fig. 3 ). Conversely, 3D growth 89 was dependent on the expression of oncogenic Kras ( Supplementary Fig. 2 ), mimicking the requirement 90 for oncogenic Kras in vivo. We used the 3D system to study the effect of inhibiting Kras* downstream 91 effector pathways, specifically MAPK and PI3K, in the tumor cells. First, we performed immunostaining 92 on iKras*p53* PDAC clusters grown in the presence of DOX for 6 days. Similar to human PDAC and tissue 93 from the primary iKras*p53* tumor ( Fig. 2 a, b ), iKras*p53* PDAC cells in 3D culture upregulated 94 phosphorylated ERK (pERK) ( Fig. 2a ) and phosphorylated S6 (pS6) ( Fig. 2b ), indicating activation of the 95 MAPK and PI3K pathway, respectively. Furthermore, we observed expression of membrane proteins E-96
Cadherin and Claudin-18 ( Fig. 2c -j), both epithelial cell markers. Taken together, these data suggest two 97 implications for our system. First, iKras*p53* PDAC cells in our 3D culture system recapitulate common 98 biological characteristics of human PDAC and other murine in vivo models. Second, it can be used to 99 study the effect of signaling pathways in a system that mimics the spatial relationships of tumor cells, 100 while allowing us to dissect signaling, in absence of the complexity of the microenvironment. 101
102

MEK inhibition inhibits PDAC growth in 3D and induces apoptotic lumen formation 103
To inhibit MAPK signaling, clusters were grown for 6 days and then administered PD325901 (MEK 104 inhibitor, abbreviated MEKi-P) for 4 days; DOX was present in the media at all points, so that oncogenic 105 Kras* was constitutively expressed. Administration of the inhibitor was sufficient to abrogate Kras*-106 mediated cluster growth ( Fig. 3a-e ). Upon histologic analysis we found that MEK inhibition decreased 107 the expression of pERK, suggesting successful inactivation of the MAPK signaling pathway ( Fig. 3f -i). 108
However, similar to the in vivo situation, cultures survived, indicating resistance to MEK inhibition. The 109 MEK-resistant cells formed single-layer clusters, while the lumen (occupying >75% of cross-section area) 110 6 contained apoptotic debris. This finding was dose-dependent ( Fig. 3j ), as increasing concentration of 111
MEKi led to increased prevalence of single-layered clusters with large lumens. These results suggested 112 that cells at the periphery of the cluster, and thus in contact with the basement membrane, were 113 uniquely resistant to MEK inhibition. Intriguingly, this finding recapitulated what we and others 114 observed in vivo upon inactivation of oncogenic Kras [13, 15] . 115
116
To confirm this initial finding with a different MEK inhibitor, PDAC cells were grown for 1 week and 117 administered a clinically available MEK inhibitor, trametinib (MEKi-T) for 4 days. To visualize any 118 morphologic changes induced by MEK inhibition, PDAC clusters were fixed, sectioned, and stained for 119 hematoxylin and eosin. Similar to clusters treated with MEKi-P, MEKi-T treated clusters were found to 120 have an apoptotic lumen--evidenced by unorganized hyaline aggregation as well hyperchromatic debris, 121 which indicates nuclear fragmentation, features consistent with cells that undergo programmed cell 122 death (Fig. 4c ). The prevalence of clusters with apoptotic debris that occupied >75% of a single lumen 123 was found to be significantly increased approximately 7-fold following MEK-T administration ( Fig. 4d ). To 124 establish that the cells had indeed undergone apoptosis, we stained sections of PDAC clusters for 125 cleaved caspase-3 (CC3) ( Fig. 4a, b ). Thus, using two different MEK inhibitors, we showed that cancer 126 cells vary in their sensitivity to MEK inhibition. 127
128
PDAC cells adjacent to Matrigel display a survival advantage 129
The prevalence of single-layer cluster morphology suggests that cells in contact with the Matrigel 130 7 staining for Type IV collagen (Col4), a primary component of Matrigel and the basement membrane in 134 vivo. Staining reveals Col4 enrichment on the outer edge of clusters treated with either vehicle (DMSO) 135 or MEKi-T, suggesting that MEK inhibition does not affect organization of basement membrane ( Fig. 5a ). 136
Upon quantification of cells adjacent or nonadjacent to Matrigel, the MEK-T treated clusters showed an 137 increased prevalence of cells adjacent to the Matrigel, suggesting that these cells have a survival 138 advantage over cells that lack ECM attachment (Fig. 5b ). The phenomenon of anoikis, a form of 139 programmed cell death in response to loss of ECM signaling, is well described in other systems. [16] . We 140 hypothesized that Matrigel-adjacent cells were able to resist anoikis due to their ability to interact and 141 exchange signals with ECM components. 142 143 Human and murine PDAC cells have been shown to engage in complex signaling with the surrounding 144 microenvironment, yet the implications of this signaling and their effects on disease pathogenesis are 145 currently poorly understood. In multiple systems, the transmembrane, bidirectional signaling molecule 146 β1 integrin has been implicated in coordinating cell-to-cell and cell-to-ECM interactions [17] . And in the 147 normal pancreas, β1 integrin expression is necessary for acinar maintenance [18] . In our 3D system, we 148 found that iKras*p53* PDAC cells expressed β1 integrin ( Supplementary Fig. 4 ), and this expression was 149 not affected by administration of MEKi-T ( Supplementary Fig. 4 ). Given that Matrigel-adjacent PDAC 150 cells show a survival advantage and express β1 integrin, we hypothesized that β1 integrin signaling 151 mediated survival in this population. 152 153
Beta-1 integrin inhibition disrupted cell:cell organization and decreased Kras effector signaling 154
The function of β1 integrin is highly dependent on cell type as well as the cell's immediate 155 microenvironment [19, 20] . To determine the functional importance of β1 integrin signaling in our 3D 156 8 culture model, PDAC clusters were grown for 7 days and treated with either solubilized rat 157 immunoglobulin G (IgG) or a β1 integrin neutralizing antibody [ Supplementary Table 1] Matrigel-adjacent and non-Matrigel-adjacent cells indicated by positive staining of pERK and pS6 ( Fig. 7  178 b, l, Supplementary fig. 4 ). Strikingly, following β1 integrin blockade, Kras* effector signaling was 9 restricted to Matrigel-adjacent cells ( Fig. 7 g, q) . Though β1-integrin-blocked PDAC clusters showed 180 some localization of β1 integrin to the ECM ( Fig. 7 h, r), colocalization of β1 integrin and pERK or pS6 181 signals was rare ( Fig. 7 i, s) . These results suggest that β1 integrin signaling is necessary for PDAC 182 upregulation of Kras* downstream signaling in the absence of ECM signaling in our system. 183 Prior studies have demonstrated that epithelial cell lumen formation is an active process that requires 188 both cell:cell adhesion and cell:ECM signaling. Since lumen formation appears to be protective for PDAC 189 cells in the context of MEK inhibition (Fig. 4d, 5b) and β1 integrin was necessary for lumen formation in 190 our model ( Fig. 6g-j) , we hypothesized β1 integrin signaling blockade would prevent lumen formation 191 and potentiate the ability of MEK inhibition to induce apoptosis. To test this, PDAC cells were grown in 192 3D for 7 days and treated for 4 days with vehicle (DMSO+IgG), MEK-T, an anti-β1 integrin neutralizing 193 antibody, or a combination of the compounds. Subsequently, PDAC clusters were fixed, sectioned and 194 prepared for immunofluorescence to examine CC3 or TUNEL staining. Singular administration of either 195 MEK-T or anti-β1 integrin neutralizing antibody increased apoptosis, as indicated by increased CC3 196 staining, compared to the vehicle group ( Fig. 8a-p, Supplementary Fig. 6 ). Furthermore, dual inhibition 197 led to significantly increased apoptosis when compared to singular blockade of either pathway (Fig. 8q ). 198 TUNEL staining demonstrated similar findings: singular blockade of either MEK or β1 integrin 199 significantly increased cell death, while clusters in the dual blockade group showed significantly 200 increased death when compared to singular blockade of either pathway (Figure 8r, s) . These results, 201 taken together, suggest that β1 integrin signaling mediates PDAC resistance to MEK inhibition. 
